Impact of combination therapy on Ki-67 and Bcl-2 expression in psoriasis

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory immune-mediated disease characterized by an increased rate of keratinocyte division. Modern ideas about the immunopathogenesis of psoriasis, systemic inflammation and manifestations, comorbid conditions bring to the fore the question of the rational choice of therapy in patients with moderate and severe psoriasis.

AIM: to study the effect of the combined use of PUVA therapy and methotrexate on the expression levels of receptors for the proliferation marker Ki-67 and the anti-apoptotic protein Bcl-2.

MATERIALS AND METHODS: The study included 110 patients with moderate to sеvеrе psоriаsis,divided into 2 groups: the first group received PUVA therapy in combination with methotrexate (Mt); the second group received methotrexate (Mt) monotherapy. Skin biopsies were taken from the affected areas in 10 patients from the 1st group before and after therapy for immunohistochemical study to determine the level of expression of Ki-67 and Bcl-2. Healthy skin bioptats were taken from patients operated on for appendicitis and used as the control samples.

RESULTS: An immunohistochemical study revealed a statistically significant increase in the initial indicators of the expression level of Ki-67 and Bcl-2 in all patients with psoriasis compared with the control group. As a result of the combined therapy, there was a significant decrease in the expression of Ki-67 and Bcl-2.

CONCLUSION: The combined method of treatment of patients with psoriasis has an immunosuppressive effect, as evidenced by a significant decrease in the expression of the proliferation marker Ki-67 and the apoptosis inhibitor Bcl-2.

Keywords

psoriasis / PUVA therapy / methotrexate / Ki-67 / Bcl-2

References

[1] Gudinova ZV, Okhlopkov VA, Poleshchuk EI, Zhernakova GN. Incidence of psoriasis depending on the region of the Russian Federation. Russ J Skin Venereal Dis. 2018;(2):85–89. (In Russ).

[2] Гудинова Ж.В., Охлопков В.А., Полещук Е.И., Жернакова Г.Н. Заболеваемость псориазом в зависимости от региона Российской Федерации // Российский журнал кожных и венерических болезней. 2018. № 2. С. 85–89.

[3] Parisi R, Symmons D, Griffiths C, Ashcroft D. Global epidemiology of psoriasis: A systemic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339

[4] Parisi R., Symmons D., Griffiths C., Ashcroft D. Global epidemiology of psoriasis: A systemic review of incidence and prevalence // J Investigative Dermatol. 2013. Vol. 133, N 2. P. 377–385. doi: 10.1038/jid.2012.339

[5] Gupta R, Michaud H, Zeng X, et al. Diminished humoral responses against and reduced gene expression levels of human endogenous retrovirus-K (HERV-K) in psoriasis. J Transl Med. 2014;(12):256. doi: 10.1186/s12967-014-0256-4

[6] Gupta R., Michaud H., Zeng X., et al. Diminished humoral responses against and reduced gene expression levels of human endogenous retrovirus-K (HERV-K) in psoriasis // J Transl Med. 2014. N 12. P. 256. doi: 10.1186/s12967-014-0256-4

[7] Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27. doi: 10.1007/s00281-015-0539-8

[8] Mahil S.K., Capon F., Barker J.N. Update on psoriasis immunopathogenesis and targeted immunotherapy // Semin Immunopathol. 2016. Vol. 38, N 1. P. 11–27. doi: 10.1007/s00281-015-0539-8

[9] Remröd C, Sjöström K, Svensson A. Subjective stress reactivity in psoriasis: A cross sectional study of associated psychological traits. BMC Dermatol. 2015;(15):6. doi: 10.1186/s12895-015-0026-x

[10] Remröd C., Sjöström K., Svensson A. Subjective stress reactivity in psoriasis: A cross sectional study of associated psychological traits // BMC Dermatol. 2015. N 15. P. 6. doi: 10.1186/s12895-015-0026-x

[11] Katunina OR. Participation of factors of innate immunity in the pathogenesis of psoriasis. Arch Pathol. 2011;(5):40–43. (In Russ).

[12] Катунина О.Р. Участие факторов врожденного иммунитета в патогенезе псориаза // Архив патологии. 2011. № 5. С. 40–43.

[13] Bogadelnikova AE, Olisova OY, Vladimirov VV, Mikryukov AV. Treatment of patients with atopic dermatitis using selective phototherapy with UV rays 311 nm. Russ J Skin Venereal Dis. 2007;(2):30–34. (In Russ).

[14] Богодельникова А.Е., Олисова О.Ю., Владимиров В.В., Микрюков А.В. Лечение больных атопическим дерматитом с применением селективной фототерапии УФ-лучами 311 нм // Российский журнал кожных и венерических болезней. 2007. № 2. С. 30–34.

[15] Miossec P, Kolls JK. Targeting IL-17 and Th17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–776. doi: 10.1038/nrd3794

[16] Miossec P., Kolls J.K. Targeting IL-17 and Th17 cells in chronic inflammation // Nat Rev Drug Discov. 2012. Vol. 11, N 10. P. 763–776. doi: 10.1038/nrd3794

[17] Samtsov AV, Khairutdinov VR, Bakulev AL, et al. Efficacy and safety of BCD-085, an original monoclonal antibody against interleukin-17 in patients with moderate to severe psoriasis vulgaris. Results of the Phase II international multicenter comparative randomized double-blind placebo-controlled clinical trial. Bulletin Dermatol Venereol. 2017;(5):52–63. (In Russ).

[18] Самцов А.В., Хайрутдинов В.Р., Бакулев А.Л., и др. Эффективность и безопасность препарата BCD-085 ― оригинального моноклонального антитела против интерлейкина-17 у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Результаты II фазы международного многоцентрового сравнительного рандомизированного двойного слепого плацебоконтролируемого клинического исследования // Вестник дерматологии и венерологии. 2017. № 5. C. 52–63.

[19] Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–150. doi: 10.1016/j.jaad.2013.12.036

[20] Lynde C.W, Poulin Y., Vender R., et al. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis // J Am Acad Dermatol. 2014. Vol. 71, N 1. P. 141–150. doi: 10.1016/j.jaad.2013.12.036

[21] Kruglova LS, Ponich ES, Mosina AV, Gryaznova NV. About the features of the use of cyclosporine in psoriasis (review). Saratov Sci Med J. 2017;13(3):673–678. (In Russ).

[22] Круглова Л.С., Понич Е.С., Осина А.В., Грязева Н.В. Оценка эффективности применения циклоспорина при псориазе (обзор) // Саратовский научно-медицинский журнал. 2017. Т. 13, № 3. C. 673–678.

[23] Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116(12):3183–3194. doi: 10.1172/JCI28756

[24] Rangel-Moreno J., Hartson L., Navarro C., et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis // J Clin Invest. 2006. Vol. 116, N 12. P. 3183–3194. doi: 10.1172/JCI28756

[25] Nasr IW, Reel M, Oberbarnscheidt MH, et al. Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection. Am J Transplant. 2007;7(5):1071–1079. doi: 10.1111/j.1600-6143.2007.01756.x

[26] Nasr I.W., Reel M., Oberbarnscheidt M.H., et al. Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection // Am J Transplant. 2007. Vol. 7, N 5. P. 1071–1079. doi: 10.1111/j.1600-6143.2007.01756.x

[27] Perlamutrov YN, Olkhovskaya KB, Soloviev AM, Aivazova TV. Experience of using a phosphodiesterase inhibitor type 4 in patients with psoriasis. Consilium Medicum. Dermatology. 2018;(4):24–29. (In Russ).

[28] Перламутров Ю.Н., Ольховская К.Б., Соловьев А.М., Айвазова Т.В. Опыт применения ингибитора фосфодиэстеразы 4-го типа у больных псориазом // Consilium Medicum. Дерматология. 2018. № 4. С. 24–29.

[29] Kim SA, Ryu YW, Kwon JI, et al. Differential expression of cyclin D1, Ki-67, pRb, and p53 in psoriatic skin lesions and normal skin. Mol Med Rep. 2018;17(1):735–742. doi: 10.3892/mmr.2017.8015

[30] Kim S.A., Ryu Y.W., Kwon J.I., et al. Differential expression of cyclin D1, Ki-67, pRb, and p53 in psoriatic skin lesions and normal skin // Mol Med Reports. 2018. Vol. 17, N 1. P. 735–742. doi: 10.3892/mmr.2017.8015

[31] Amany B, Ahmed B. Study of keratinocyte proliferation, apoptosis, and dermal inflammation in psoriatic skin lesions before and after methotrexate therapy: Which change is contributing more to the clinical severity of the disease? Am J Res Med Sci. 2018;2(1):34–43. doi: 10.5455/ajrms.281926

[32] Amany B., Ahmed B. Study of keratinocyte proliferation, apoptosis, and dermal inflammation in psoriatic skin lesions before and after methotrexate therapy: Which change is contributing more to the clinical severity of the disease? // Am J Res Med Sci. 2018. Vol. 2. N 1. P. 34–43. doi: 10.5455/ajrms.281926

[33] Jesionek-Kupnicka D, Chomiczewska-Skora D, Rotsztejn H. Infuence of phototherapy in psoriasis on KI-67 antigen expression: A preliminary study. Pol J Pathol. 2013;64(2):96–103. doi: 10.5114/PJP.2013.36006

[34] Jesionek-Kupnicka D., Chomiczewska-Skora D., Rotsztejn H. Infuence of phototherapy in psoriasis on KI-67 antigen expression: A preliminary study // Pol J Pathol. 2013. Vol. 64, N 2. P. 96–103. doi: 10.5114/PJP.2013.36006

RIGHTS & PERMISSIONS

Melikova N.I., Tashkenbaeva U.A.